China, September 17, 2026
IASO Bio has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for IASO208, an investigational CD20-targeted in vivo CAR-T therapy. The regulatory milestone enables the company to advance IASO208 into clinical development in the United States and represents a significant step for the emerging field of in vivo chimeric antigen receptor T-cell (CAR-T) therapy. Unlike conventional CAR-T approaches, which generally require immune cells to be collected from a patient and genetically modified outside the body before being reinfused, IASO208 is designed to generate CAR-T cells directly inside the patient’s body. The therapy is being developed to target CD20, a protein expressed on B cells and associated with several B-cell malignancies. The FDA IND clearance provides a regulatory pathway for clinical investigation of the candidate’s safety and potential therapeutic activity.
IASO208 Advances In Vivo CAR-T Development
IASO208 is designed as an in vivo CAR-T therapy targeting CD20-positive cells, with the objective of overcoming some of the manufacturing and treatment complexities associated with conventional autologous CAR-T therapies. Traditional CAR-T treatment involves collecting a patient’s T cells, genetically engineering those cells to express a cancer-targeting CAR, expanding the modified cells under controlled manufacturing conditions and subsequently administering them back to the patient. This process can require substantial time, specialized manufacturing infrastructure and individualized production for each patient.
In vivo CAR-T technology seeks to move part of this process inside the patient, using a delivery system to introduce genetic instructions into T cells so that they can acquire CAR expression within the body. IASO208 represents IASO Bio’s effort to apply this approach to CD20-directed cancer therapy. If successful in clinical development, an in vivo strategy could potentially provide a more streamlined therapeutic manufacturing model while enabling broader exploration of CAR-T treatment. However, IASO208 remains investigational, and its clinical safety, efficacy and practicality will need to be established through human studies.
CD20 Target Provides Established Oncology Rationale
Advertisement
The therapeutic strategy behind IASO208 centers on CD20, a well-established target in B-cell oncology. CD20 is expressed on the surface of many malignant B cells and has already been successfully targeted by several antibody-based cancer therapies. CAR-T technology can potentially harness the patient’s own T cells to recognize and eliminate cells carrying the selected target. By combining CD20 targeting with in vivo CAR-T generation, IASO Bio is pursuing an approach intended to bring the potent immune-cell-mediated mechanisms of CAR-T therapy into a potentially more accessible treatment format. The company’s broader research platform focuses on developing innovative cell therapies designed to address serious diseases. The FDA IND clearance marks the transition of IASO208 from preclinical development toward formal clinical evaluation in the United States.
The regulatory milestone is particularly relevant as researchers continue investigating ways to make CAR-T therapies faster, more scalable and potentially easier to manufacture. Conventional CAR-T therapies have demonstrated clinical benefits in certain hematological cancers, but their complex production processes and individualized manufacturing requirements remain important considerations in treatment development.
FDA Clearance Opens Path to Clinical Evaluation
The FDA’s IND clearance allows IASO Bio to proceed with the clinical development program for IASO208 under applicable regulatory requirements. The upcoming clinical studies are expected to provide the first important human data needed to evaluate the therapy’s safety, tolerability, pharmacological activity and potential antitumor effects. As with other investigational CAR-T therapies, researchers will closely monitor treatment-related immune effects and other potential safety considerations during clinical development. The advancement of IASO208 also highlights the growing scientific interest in in vivo cell therapy, an area that aims to simplify the delivery of genetically engineered immune-cell therapies. Rather than relying entirely on individualized ex vivo manufacturing, these approaches seek to engineer therapeutic cells within the patient. The FDA IND clearance therefore represents an important development for IASO Bio and contributes to the expanding clinical pipeline of next-generation cell and gene therapies.
Future clinical data will determine whether IASO208 can demonstrate a favorable balance of safety and therapeutic activity in patients with CD20-positive diseases. For now, the FDA clearance provides IASO Bio with the regulatory opportunity to begin clinical investigation and further evaluate the potential of in vivo CAR-T technology in oncology.
Source: IASO Bio press release
